Cannabidiol not checked
Jazz Pharmaceuticals · JZP926 · GWP42003
FollowEvery change as it happens, and a Monday email
Trials
17 active
51 in total · 25 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Starting dose of CBD-OS will be administered as per the approved local product label”In the company’s words, NCT07233239 on ClinicalTrials.gov
- Tested for
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex, Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathy (DEE), Juvenile Myoclonic Epilepsy, Focal Seizures
- Main trialPhase 4
- “This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.”In the company’s words, NCT05044819 on ClinicalTrials.gov
- Other names
- JZP926 · CBD-OS · Epidiolex · Epidyolex · GWP42003 · CBD · GWP42003-P · JZP926-OS
Other drugs for Lennox Gastaut Syndrome
- CarisbamateSK Life Science, Inc. · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- Clemizole HClEpygenix · Phase 3
- BMB-101Bright Minds Biosciences · Phase 2
Coming up5
- 1 Aug 2027Phase 4 trial completes · ClinicalTrials.gov
- 29 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
- 1 Aug 2028Phase 2/3 trial completes · ClinicalTrials.gov
- 28 Dec 2028Phase 4 trial completes · ClinicalTrials.gov
- 4 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07723976
Trials51
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 1 Aug 2027 | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | |
| Phase 4Not yet recruiting | 28 Dec 2028 | A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS | |
| Phase 3Recruiting | 4 Sep 2029 | A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE | |
| Phase 2/3Recruiting | 1 Aug 2028 | A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy | |
| Phase 1Recruiting | 29 Nov 2027 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | |
| Phase 4Withdrawn | Dec 2021 | Investigation of Cognitive Outcomes With Cannabidiol Oral Solution | |
| Phase 4Completed | 6 Apr 2026 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex | |
| Phase 3Completed | 26 Nov 2015 | Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) | |
| Phase 3Completed | 18 Mar 2016 | A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | |
| Phase 3Completed | 19 May 2016 | Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | |
| Phase 3Completed | 9 Apr 2018 | GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome | |
| Phase 3Completed | 7 May 2018 | Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) | |
| Phase 3Completed | 22 Jan 2019 | A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | |
| Phase 3Completed | 13 Jun 2019 | Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) | |
| Phase 3Terminated | 21 Jan 2021 | Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | |
| Phase 3Terminated | 9 Jun 2021 | A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | |
| Phase 3Completed | 11 Jun 2021 | An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | |
| Phase 3Terminated | 28 Sep 2023 | Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures | |
| Phase 3Terminated | 28 Jan 2025 | Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | |
| Phase 2Completed | May 2012 | GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes | |
| Phase 2Completed | 8 Jan 2015 | A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder | |
| Phase 2Completed | 9 Mar 2015 | A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) | |
| Phase 2Completed | 21 Jul 2016 | A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol | |
| Phase 2Completed | 7 Jun 2017 | An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol | |
| Phase 2Completed | 11 Sep 2018 | A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | |
| Phase 2Completed | 27 May 2019 | An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | |
| Phase 2Terminated | 16 Mar 2022 | Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment | |
| Phase 2Completed | 21 Dec 2023 | Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | |
| Phase 2Authorised | not given | Open-label pilot study to assess the efficacy and safety of Cannabidiol oral solution as an adjunctive treatment for children and young adults with rare disease-associated severe epilepsy | |
| Phase 2Not authorised | not given | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) | |
| Phase 2Not authorised | not given | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) | |
| Phase 2Authorised | not given | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) | |
| Phase 3Not authorised | not given | Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA) | |
| Phase 3Authorised | not given | Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA) | |
| Phase 2Ended | not given | Explorative, randomized, double-blind, placebo-controlled, 3-way cross-over study to assess the effects of oral cannabidiol 30 and 700 mg in healthy male subjects on CNS and cortical excitability using the NeuroCart test battery and TMS. | |
| Phase 2Authorised | not given | Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan) | |
| Phase 2Authorised | not given | A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with untreatable advanced hepatocellular carcinoma - the CanHep study | |
| Phase 2Ended | not given | Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study. | |
| Phase 2Ended | not given | A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting with Symptoms Associated with Irritable Bowel Syndrome with code GSL-01-001 | |
| Phase 2Ended | not given | BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms | |
| Phase 2Halted | not given | CBD-ESPRIT - Enhancing recovery in early schizophrenia – a multi-center, two-arm, double-blind, randomized clinical trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment | |
| Phase 2/3Ended | not given | Cannabidiol for treatment of non-affective psychosis and cannabis use | |
| Phase 2Ended | not given | Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study | |
| Phase 2Authorised | not given | ICONICplus - Randomized, double-blind, placebo-controlled trial to investigate the Effects of Cannabidiol plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence | |
| Phase 2Ended | not given | The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo-controlled N-of-1 trials | |
| Phase 2Authorised | not given | CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II trial | |
| Phase 2Authorised | not given | The effect of CBD on sleep quality following late evening exercise | |
| Phase 2Authorised | not given | PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial | |
| Phase 3Authorised | not given | Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series | |
| Phase 2Authorised | not given | CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders | |
| Phase 3Authorised | not given | AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026